Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Interleukin (IL)-4 Antibody Market Size, Value And Growth Trajectory Through 2030
The market size for interleukin (il)-4 antibodies has shown significant growth in recent years. This market is anticipated to expand from $2.32 billion in 2025 to $2.53 billion in 2026, progressing at a compound annual growth rate (CAGR) of 8.8%. The historical growth of this market can be linked to factors such as increased research in allergy and asthma, the rising utilization of cytokine assays, the expansion of academic immunology studies, enhanced availability of monoclonal antibody platforms, and an increase in biomedical research funding.
The interleukin (il)-4 antibody market is projected to experience robust expansion in the coming years. This market is anticipated to reach $3.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This forecasted growth is attributable to factors such as the escalating demand for precision immunomodulators, the broadening scope of autoimmune disease research, increasing capital injection into biologics development, an amplified emphasis on translational research applications, and the wider integration of advanced immunoassays. Key developments expected during this period involve the increasing application of il-4 antibodies in immunology studies, the progressive creation of targeted immunotherapies, the wider acceptance of high-specificity monoclonal antibodies, the broader utility of cytokine profiling applications, and a heightened commitment to antibody validation benchmarks.
Get A Free Sample Report With In-Depth Market Insights:
Interleukin (IL)-4 Antibody Market Growth Factors Behind Sustained Expansion
The growing incidence of allergic diseases is anticipated to fuel the expansion of the interleukin (IL)-4 antibody market in the future. Allergic diseases are immune system disorders where the body reacts excessively to harmless substances like pollen, dust, or food, leading to symptoms such as inflammation, itching, and breathing difficulties. The heightened prevalence of these conditions is attributed to urbanization and environmental shifts, which lead to increased exposure to pollutants and allergens that trigger immune overreactions. Interleukin (IL)-4 antibody assists in managing allergic diseases by specifically targeting IL-4 pathways, proving effective in reducing immune system overreactions. This alleviates symptoms such as inflammation, itching, and breathing difficulties, thereby enhancing patient comfort and quality of life. For instance, in February 2025, according to the National Asthma Council Australia (NAC), an Australia-based not-for-profit organization, Australia recorded a total of 474 asthma-related deaths, representing a marginal year-on-year increase of 0.2% from 473 deaths in 2022, with females accounting for 68.6% (325 deaths) and males comprising 31.4% (149 deaths). Therefore, the increasing prevalence of allergic diseases is driving the growth of the interleukin (IL)-4 antibody market.
Interleukin (IL)-4 Antibody Market Segment Landscape And Growth Outlook
The interleukin (il)-4 antibody market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Polyclonal Antibodies
2) By Application: Enzyme Linked Immunosorbent Assay, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Western Blot, Other Applications
3) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs)
Subsegments:
1) By Monoclonal Antibodies: Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Murine Monoclonal Antibodies
2) By Polyclonal Antibodies: Rabbit Polyclonal Antibodies, Goat Polyclonal Antibodies, Sheep Polyclonal Antibodies, Mouse Polyclonal Antibodies, Donkey Polyclonal Antibodies
Interleukin (IL)-4 Antibody Market Industry Trends Fueling Future Revenue Growth
Within the interleukin (IL)-4 antibody market, major companies are directing their efforts toward developing innovative products, such as next-generation bispecific antibodies, to overcome tumor resistance and improve anti-cancer efficacy. Next-generation bispecific antibodies are engineered to simultaneously attach to two distinct antigens or epitopes, thereby enhancing therapeutic effectiveness by modulating multiple pathways concurrently, improving specificity, and potentially reducing side effects compared to traditional single-target antibodies. As an example, in February 2025, Akeso Inc., a China-based biopharmaceutical company, obtained Investigational New Drug (IND) acceptance from the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody. AK139 integrates dual targeting of interleukin-4 receptor alpha and the ST2 receptor to block the interleukin-4/interleukin-13 and interleukin-33 pathways simultaneously, delivering mechanistic synergy beyond single-target antibodies. This design seeks to more effectively diminish inflammatory cytokine release and tissue infiltration, potentially offering stronger and more durable control of type-2 and related inflammation in respiratory and dermatological diseases.
Interleukin (IL)-4 Antibody Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the interleukin (il)-4 antibody market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., GeneTex Inc., Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, Cell Signaling Technology Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Santa Cruz Biotechnology Inc., Atlas Antibodies AB, Creative Biolabs Inc., Abnova (Taiwan) Corporation, Wuhan Fine Biotech Co. Ltd., United States Biological LLC, NSJ Bioreagents, Boster Biological Technology Co. Ltd.
View The Full Interleukin (IL)-4 Antibody Market Report:
Interleukin (IL)-4 Antibody Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the interleukin (IL)-4 antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin (il)-4 antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
